Journal
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS
Volume 2, Issue -, Pages 809-824Publisher
SAGE PUBLICATIONS LTD
DOI: 10.4137/CMT.S5884
Keywords
galantamine; dementia; randomized controlled trial; systematic review; meta analysis
Categories
Funding
- Province of Ontario's Ministry of Health and Long-Term Care
- McLaughlin Professorship in Population and Public Health
Ask authors/readers for more resources
We conducted a systematic review and meta analysis of randomized controlled trials of galantamine hydrobromide in the treatment of mild to moderate dementia. Following a literature search and screening process, we included 15 trials and five companion papers in the review. Moderate-quality evidence suggested galantamine-treated persons generally had better outcomes than placebotreated persons after a maximum 6-month follow-up. Outcome domains included cognitive function, global function, behaviour and mood, and activities of daily living. The evidence requires careful interpretation because 'better outcomes' can mean less deterioration, rather than improvement, relative to placebo. Galantamine has not been shown to halt dementia progression nor reverse disease course. The most frequently reported harms were nausea, diarrhea, and dizziness. Reported rates of these harms were highly variable (range, 0%-40%); reporting was at high risk of bias because authors rarely specified the frequency or timing of harms assessment, nor did they report active methods of collecting harms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available